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Abstract. We analyzed characteristics of humanitarian service workers (HSWs) seen pre-travel at Global TravEpiNet
(GTEN) practices during 2009–2011. Of 23,264 travelers, 3,663 (16%) travelers were classified as HSWs. Among HSWs,
1,269 (35%) travelers were medical workers, 1,298 (35%) travelers were non-medical service workers, and 990 (27%)
travelers were missionaries.Median age was 29 years, and 63% of travelers were female. Almost one-half (49%) traveled to
1 of 10 countries; the most frequent destinations were Haiti (14%), Honduras (8%), and Kenya (6%). Over 90%
of travelers were vaccinated for or considered immune to hepatitis A, typhoid, and yellow fever. However, for hepatitis B,
292 (29%) of 990 missionaries,228 (18%) of 1,298 non-medical service workers, and 76 (6%) of 1,269 medical workers were
not vaccinated or considered immune. Of HSWs traveling to Haiti during 2010, 5% of travelers did not receive malaria
chemoprophylaxis. Coordinated efforts from HSWs, HSW agencies, and clinicians could reduce vaccine coverage gaps
and improve use of malaria chemoprophylaxis.
INTRODUCTION
Global humanitarian staffing levels for internationally oper-
ating aid organizations have increased at a rate of 6% annually,
and in 2008, they reached a total population of roughly 595,000
humanitarian service workers (HSWs) worldwide.
1 HSWs can
include missionaries, medical service workers, or individuals
traveling overseas to perform short- or long-term humanitarian
work. Because of the nature of their work,
2,3 lengthof stay,
4 and
travel destinations, which are primarily low-resource countries,
HSWs face different risks of illness and injury than persons
traveling for other purposes.
3,5,6 There have been numerous
reports of HSWs returning home ill, including those HSWs
who were responding to complex overseas emergencies.
7–10 A
recent study found that, among 185 ill travelers returning home
from Haiti in 2010, 142 (77%) travelers were providing human-
itarian assistance after the January of 2010 earthquake.
8
An accurate percentage of HSWs seeking pre-travel prepa-
rations is not known, and previous studies of ill HSW travelers
vary greatly in their estimates (15–71%).
7,8,11 Furthermore,
travelers who do access health resources before departure may
not always receive the most up-to-date recommendations.
12
Although pre-travel healthcare cannot guarantee a traveler’s
health and safety, a well-organized and -executed consultation
can use counseling, education, and administration of vaccines
and prescriptions to help reduce and manage the risk of illness
and injury during travel.
13
We sought to describe characteristics of HSWs traveling
abroad from the United States to identify opportunities to
target preventive interventions for these unique populations.
METHODS
Study population. The Global TravEpi Network (GTEN)
Consortium is a national network of US practices that provide
pre-travel health consultations to international travelers.
14
Data from consultations were collected from travelers seen
at 1 of 18 GTEN practices from January of 2009 through
December of 2011. An institutional review board at each
participating site reviewed and approved the study.
For each consultation, travelers self-reported their medical
history, itinerary, and travel purpose details. Clinicians veri-
fied this information with the traveler and entered additional
data on vaccination history, health advice provided, vaccines
administered, and medications prescribed into the GTEN
online tool. No serologic tests were conducted to confirm
immunity. If a vaccine was indicated according to current
recommendations of the US Centers for Disease Control and
Prevention (CDC) but not administered at the pre-travel visit,
the clinician was prompted to provide a reason for not admin-
istering the vaccine, such as the traveler’s pre-existing immu-
nity, the clinician’s belief that the vaccine was not indicated,
referral of the patient to another provider for vaccination,
the traveler declined the vaccine, the clinician’s assessment
that a medical contraindication to vaccination existed, lack of
sufficient time for vaccination, or lack of availability of the
vaccine. For rabies vaccine, clinicians were prompted to pro-
vide a reason if the vaccine was not recommended for those
HSWs traveling ³ 1 month (28 days).
Definitions and variables. Travelers reporting missionary
work, medical care, or non-medical service work as their pur-
pose of travel were considered HSWs in this analysis. For
comparative analyses, HSWs were grouped into one of three
categories (missionary, medical, or non-medical). Medical
workers included all HSWs who indicated performing medical
service or any combination of medical work and other human-
itarian service. Those HSWs who indicated that they were
performing both missionary and non-medical work were
included in the overall analysis but excluded from compara-
tive analyses between different categories of HSWs. Children
under 18 years of age and those indicating a purpose of travel
other than missionary, medical, or non-medical were excluded
from the analyses.
We evaluated the proportion of GTEN travelers vacci-
nated for the following diseases: hepatitis A, hepatitis B,
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553measles-mumps-rubella (MMR), tetanus-diphtheria-pertussis
(Td/Tdap), varicella, typhoid, rabies, polio, meningococcal
disease, Japanese encephalitis (JE), and yellow fever (YF).
For this analysis, hepatitis B, Td/Tdap, MMR, and varicella
vaccines were defined as generally recommended for all
HSWs before departure if they were not already immune.
The proportion of travelers vaccinated for hepatitis A,
typhoid, rabies, polio, meningococcal disease, JE, and YF was
assessed for specific groups of at-risk HSWs who met criteria
(e.g., destination country with risk or season with risk) for
recommended vaccination based on the most current CDC
recommendations available at the time of the consulta-
tion.
13,15,16 Specifically, rabies vaccination status was assessed
for queried travelers who went to countries considered at the
highest risk for rabies exposure. A more extensive description of
this rabies exposure risk methodology is provided elsewhere.
17
Vaccination status for YF and JE was assessed only for those
HSWs traveling to areas of known risk according to the most
current CDC recommendations available at the time of pre-
travel consultation.
18,19 Travelers going to destinations with
risk for YF virus transmission were defined as those travelers
visiting countries considered entirely endemic (where YF vac-
cine should always be recommended unless there is a contra-
indication) or partially endemic and for which the provider
noted that YF vaccine was indicated by the traveler’s stated
itinerary. Travelers going to partially endemic countries and
for whom the provider chose “vaccination not indicated for this
itinerary” were excluded from YF vaccine analyses. JE vaccine
was considered to be indicated for travelers going to an
endemic country for 30 or more days during the peak season
of JE transmission and who traveled outside of an urban area,
or if they traveled fewer than 30 days and visited rural
areas exclusively.
Meningococcal vaccine was considered to be indicated for
travelers to countries in the meningitis belt of Africa during
the dry season (December to June).
15 Travelers were consid-
ered vaccinated/immune if they reported pre-existing immu-
nity from vaccination within the previous 5 years or received
quadrivalent meningococcal vaccine at the GTEN visit. A
polio booster was considered to be indicated for travelers to
polio-endemic or -epidemic areas, including countries with
recent proven wild-type polio virus circulation and neighbor-
ing countries, according to the most current travel notices
published by the CDC at the time of the pre-travel consulta-
tion. For all vaccines, if the clinician indicated existing immu-
nity or if the traveler received at least the first dose of a
vaccine series at the pre-travel consultation, the traveler was
considered vaccinated for that specific disease. Malaria
chemoprophylaxis was also assessed for HSWs traveling to
countries holoendemic for malaria according to CDC Health
Information for International Travel.
13,15
Data analysis. We obtained frequency distributions for
demographics, travel destinations, vaccinations, and type of
malaria chemoprophylaxis prescribed. A Kruskal–Wallis test
was performed to assess the relationship of age and HSW
group overall. In addition, it was used in a subanalysis of those
HSWs traveling to Haiti during 2010 to compare differences
between the HSW group and trip duration. Statistical signifi-
cance was determined at the two-sided 0.05 level. SAS 9.2
(SAS Institute, Cary, NC) was used for all analyses.
RESULTS
Demographic and trip characteristics. Of 23,264 GTEN
travelers seen at clinics during the study period, 3,663 (16%)
travelers were classified as HSWs. Among these 3,663 HSWs,
1,269 (35%) HSWs were medical workers, 1,298 (35%) HSWs
were non-medical service workers, and 990 (27%) HSWs were
missionaries (Table 1). The remaining 3% of travelers indicated
performing a combination of missionary and non-medical work.
Table 1
Demographic characteristics of HSWs by type of service performed (GTEN from January of 2009 through December of 2011)
Characteristic
Total*
(N = 3,663)
Missionary only
(N = 990)
Non-medical only
(N = 1,298)
Medical†
(N = 1,269)
Age (years)
Median (interquartile range)‡ 29 (22–45) 39 (24–53) 24 (20–36) 29 (25–38)
18–25 n (col. %)§ 1,414 (39) 276 (28) 736 (57) 372 (30)
26–45 n (col. %) 1,356 (37) 317 (32) 334 (26) 662 (52)
46–64 n (col. %) 666 (18) 324 (33) 196 (15) 207 (16)
> 65 n (col. %) 230 (6) 73 (7) 32 (2) 28 (2)
Sex n (col. %)
Female 2,295 (63) 564 (57) 845 (65) 826 (65)
Male 1,368 (37) 426 (43) 453 (35) 443 (35)
Time to departure (days)
Median (range) 28 (0–405) 32 (0–396) 29 (0–405) 25 (0–366)
Duration of travel¶(days)
Median (interquartile range) 13 (8–21) 12 (8–21) 13 (8–21) 13 (8–23)
Number of destination countries n (col. %)
1 3,020 (82) 838 (85) 1,040 (80) 1,060 (83)
2 387 (11) 98 (10) 132 (10) 140 (11)
3 123 (3) 34 (3) 53 (4) 33 (3)
³ 4 133 (4) 20 (2) 73 (6) 36 (3)
Geographic type of destination n (col. %)
Rural only 715 (19) 165 (17) 310 (24) 222 (17)
Urban only 728 (20) 219 (22) 199 (15) 288 (23)
Rural and urban 2,220 (61) 606 (61) 789 (61) 759 (60)
*Includes HSWs who indicated both missionary and non-medical service work.
†Category includes all HSWs who indicated performing medical service as well as HSWs performing any combination of medical work and other humanitarian service.
‡Non-medical service workers were significantly younger (P < 0.0001) than missionaries. Medical service workers were significantly younger (P < 0.0001) than missionaries. Non-medical
workers were significantly younger than medical workers (P < 0.0001).
§Col. % = column percent.
¶Only HSWs who traveled to one country from January of 2009 through December of 2011 were included for duration of travel.
554 STONEY AND OTHERSMissionaries were significantly older (median = 39 years) than
non-medical service workers (median = 24 years, P < 0.001)
and medical workers (median = 29 years, P < 0.001). Most
HSWs (63%) were female. HSWs attended a pre-travel health
visit a median of 4 weeks in advance of departure; most HSWs
(82%) traveled to one country. The top five destinations for all
HSWs were Haiti (14%), Honduras (8%), Kenya (6%),
Uganda (6%), and Ghana (5%). The median trip duration for
HSWs traveling abroad was 13 days.
Vaccinations. Coverage varied by vaccine and type of
humanitarian service performed (Figure 1). More than 90%
of missionaries, non-medical workers, and medical service
workers were vaccinated for or considered immune to MMR,
Td/Tdap, hepatitis A, typhoid, and YF; 292 (29%) of 990
missionaries, 228 (18%) of 1,298 non-medical service workers,
and 76 (6%) of 1,269 medical workers were not vaccinated or
considered immune for hepatitis B at the pre-travel consulta-
tion. Of these 596 HSWs, 166 (57%) of 292 missionaries, 132
(58%) of 228 non-medical service workers, and 48 (63%) of
76 medical workers did not receive vaccination because the
clinician reported the vaccine not indicated for the travelers’
itineraries. Other reasons for non-vaccination of hepatitis B
among these 596 HSWs included 124 (21%) HSWs who
declined, 84 (14%) HSWs who were referred to another
healthcare provider, and 40 (7%) HSWs who reported insuf-
ficient time to complete the vaccination series.
Among 563 HSWs indicated for meningococcal vaccine,
37 (32%) of 116 missionaries, 47 (24%) of 194 non-medical
service workers, and 31 (13%) of 233 medical workers were
not vaccinated or considered immune at the pre-travel consul-
tation. The most commonly reported reason (42%) for non-
vaccination of meningococcal disease among these 115 HSWs
was that it was not considered indicated for their itinerary. Of
31 medical workers not vaccinated for meningococcal disease,
15 (48%) HSWs declined the vaccine, and 14 (45%) HSWs
did not receive it because the clinician believed that it was
not indicated for their specific itinerary.
When a polio booster was indicated, 80 (22%) of 357 mis-
sionaries, 74 (14%) of 526 non-medical service workers, and
63 (13%) of 501 medical service workers were not vaccinated
for or considered immune to polio at the pre-travel consulta-
tion. Reasons for non-vaccination were available for 84 of
these HSWs; the most common reasons were traveler declin-
ing (58%) and clinician indicating that the vaccine was not
necessary for the itinerary (35%).
Less than 25% of HSWs with an indication for vaccination
with either JE or rabies vaccine were vaccinated or consid-
ered immune at the time of the pre-travel consultation. For
JE, 40 (44%) of 90 unvaccinated HSWs did not receive vac-
cine because the clinician considered it to be unnecessary for
the itinerary; 37 (41%) HSWs declined JE vaccination. For
rabies, 588 (74%) of 800 unvaccinated HSWs did not receive
the vaccine because the clinician considered it to be unneces-
sary for the itinerary; 145 (18%) of 800 HSWs declined
rabies vaccination.
Malaria chemoprophylaxis. Malaria chemoprophylaxes
prescribed among those HSWs traveling to the 10 most
frequented countries for HSWs are listed in Table 2. In total,
58 (7%) of 780 travelers going to Ghana, Haiti, or Uganda did
not receive malaria chemoprophylaxis at the time of the
GTEN pre-travel consultation, despite the ubiquity of malaria
in these countries. The median duration of stay for HSWs
traveling to these three countries was 10 days.
Haiti 2010 post-earthquake response. In total, 275 HSWs
traveled to Haiti during 2010 after the severe earthquake
on January 12, 2010. The median age of these HSWs was
39 years; 56% of travelers were female. Among these HSWs,
59 (21%) HSWs were missionaries, 75 (27%) HSWs were
non-medical service workers, and 129 (47%) HSWs were
medical workers. The median duration of stay for medical
Figure 1. Proportion of HSWs vaccinated or already immune at time of pre-travel consultation for vaccine-preventable diseases by type of
service performed (GTEN from January of 2009 through December of 2011). ^Category includes all HSWs who indicated performing medical
service as well as HSWs performing any combination of medical work and other humanitarian service.
PRE-TRAVEL PREP OF HUMANITARIAN SERVICE WORKERS 555workers was 14 days compared with 7 days for both mission-
aries and non-medical service workers (P < 0.0001). Two
hundred sixty-two (95%) of 275 HSWs received malaria che-
moprophylaxis for their trip, with chloroquine phosphate
being the most commonly prescribed (65%) followed by
atovaquone/proguanil (29%), doxycycline (3%), and meflo-
quine (2%). One HSW received self-treatment or termi-
nal prophylaxis.
DISCUSSION
This report summarizes pre-travel care received by HSWs
at GTEN clinics from 2009 through 2011. HSWs were pre-
dominately female (63%), and missionaries were significantly
older than other HSWs. The most common destination was
Haiti, likely attributable to relief efforts after the 2010 earth-
quake near Port au Prince.
8 Overall, HSWs attended the pre-
travel consultation a median of 4 weeks in advance of their
trip, and most HSWs were vaccinated for MMR, Td/Tdap,
hepatitis A, typhoid, and YF. However, vaccination gaps
existed for other diseases. The proportion of HSWs vacci-
nated for hepatitis B was particularly low among missionaries,
whereas gaps in both hepatitis B and meningococcal vaccines
existed among medical workers. Furthermore, some HSWs
were not vaccinated for polio or JE, even though these vac-
cines were indicated based on recommendations available at
the time of the pre-travel consultation.
We found that vaccination against hepatitis B was lower
than for other generally recommended vaccines. Specifically,
6% of medical workers were not vaccinated for or considered
immune to hepatitis B, despite Advisory Committee on
Immunization Practices (ACIP) recommendations that hepa-
titis B vaccine is indicated for all healthcare workers, regard-
less of place of practice. This vaccination is particularly
important for medical personnel working abroad in less than
optimal conditions. One explanation for the gap for medical
workers could be that few states mandate hepatitis B vaccina-
tion for healthcare workers, although some states mandate
that the vaccine be available.
20 Missionaries had the lowest
hepatitis B vaccination rate among the three categories of
HSWs. Although hepatitis B risk has been shown to be higher
in missionaries serving overseas, there are no consensus recom-
mendations for missionary health.
9,21 However, ACIP recom-
mends hepatitis B vaccination for all international travelers
going to regions with high or intermediate levels of endemic
hepatitis B infection.
20 These areas include popular missionary
destinations, such as sub-Saharan Africa, Asia, and Latin
America.
9 Despite these recommendations, a study surveying
61 missionary boards found that only 31% recommended hep-
atitis B vaccination for their staff before international travel.
9
Although cost might be a factor, we were unable to assess it in
this analysis. Because many HSWs travel repetitively, a hepati-
tis B vaccination series would provide long-term protection
for current and future trips.
22,23
We also found a gap in meningococcal vaccination among
HSWs, despite travel to at-risk countries during peak season.
Because of their age, some HSWs may not have received
the current meningococcal vaccine licensed for use in 2005
as children. In addition, routine and booster vaccination of
healthy persons not at increased risk for exposure to Neisseria
meningitidis is not recommended after age 21 years.
20 Unvac-
cinated HSWs traveling for longer durations and engaging
in activities with the local population in confined areas (e.g.,
refugee camps) may be at greater risk for meningococcal dis-
ease.
24 Although meningococcal disease incidence in most
international travelers is lower than other diseases, it has high
morbidity and mortality and should be considered in the indi-
vidual pre-travel consultation.
24
In total, 15% of HSWs were not vaccinated for or consid-
ered immune to polio, despite travel to a destination where
the vaccine was recommended. Clinicians reported that polio
vaccine was not indicated for the travel itinerary in 35% of
those HSWs not vaccinated. Despite eradication efforts, polio
continues to be a global threat, even in non-endemic coun-
tries, because of international travel.
25 From 2008 to 2010,
wild-type polio outbreaks from importations occurred in 28
countries in Africa, Eastern Europe, North Asia, and South
Asia.
26 Clinicians should stay current on recommendations
for polio vaccine by visiting the CDC Travelers’ Health
website (www.cdc.gov/travel).
16
Table 2
Prescriptions of antimalarial medications for HSWs visiting the top 10* travel destinations (GTEN from January of 2009 through December of 2011)
Country** (n, column %)
Haiti†
(N = 460)
Honduras
(N = 294)
Kenya
(N = 187)
Uganda†
(N = 137)
Ghana†
(N = 183)
India
(N = 150)
Tanzania
(N = 86)
Peru
(N = 106)
Guatemala
(N = 107)
Panama
(N = 81)
Antimalarial prescribed
Atovaquone/proguanil only 123 (27) 20 (7) 111 (59) 103 (75) 142 (78) 99 (66) 61 (71) 44 (42) 8 (7) 29 (36)
Chloroquine phosphate only 276 (60) 240 (82) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 59 (55) 41 (51)
Mefloquine only 3 (1) 1 (0.3) 20 (11) 13 (10) 9 (5) 5 (3) 4 (5) 1 (1) 0 (0) 0 (0)
Doxycycline only 9 (2) 1 (0.3) 27 (14) 16 (12) 16 (9) 26 (17) 10 (12) 5 (5) 3 (3) 4 (5)
Total‡ 419 (91) 263 (89) 161 (86) 133 (97) 170 (93) 131 (87) 76 (88) 50 (47) 70 (65) 74 (91)
Antimalarial not prescribed this visit
Referred to/received from PCP# 14 (3) 7 (2) 6 (3) 2 (1) 8 (4) 2 (1) 1 (1) 3 (3) 2 (2) 0 (0)
No information listed for traveler§ 26 (6) 22 (7) 20 (11) 2 (1) 5 (3) 17 (11) 8 (9) 47 (44) 25 (23) 7 (9)
Total¶ 41 (9) 31 (11) 26 (14) 4 (3) 13 (7) 19 (13) 10 (12) 56 (53) 37 (35) 7 (9)
*Includes the top 10 most frequently visited countries from January of 2009 through December of 2011. Only HSWs that traveled to one country from January of 2009 through December of 2011
are included.
**Countries might include both areas with and without risk for malaria unless otherwise noted. Therefore, dependent on the traveler’s itinerary, prophylaxis might not have been recommended
according to the most up-to-date CDC health information.
13,15
†Country is considered holoendemic for malaria according to the most up-to-date CDC health information.
13,15
‡Included but not listed are two travelers who were not prescribed specific antimalarial medications, but it was recorded that they received self-treatment or terminal prophylaxis. Also,
16 travelers who were prescribed more than one antimalarial at the time of the GTEN pre-travel consultation are included.
#PCP = primary care provider.
§For the time period of this report, reasons for failure to prescribe antimalarial prophylaxis were not systematically collected.
¶Others not listed here include 17 HSWs for whom the clinician stated that malaria chemoprophylaxis was not necessary (Guatemala [10], Peru [6], and Honduras [1]) and 3 HSWs who declined
(Haiti [1], Honduras [1], and Tanzania [1]).
556 STONEY AND OTHERSIn our analysis, the proportion of HSWs vaccinated for or
considered immune to rabies and JE was higher than in other
studies.
27–29 However, less than one-quarter of HSWs for
whom rabies and JE vaccinations were indicated had previous
vaccination or received vaccination at the pre-travel consulta-
tion.
27,28,30 In addition, 14% of HSWs for whom the rabies
vaccine was indicated and 32% of HSWs for whom the JE
vaccine was indicated declined vaccination. Although identi-
fying the exact reasons for declining the vaccine was beyond
the scope of this report, previous studies have found several
reasons for travelers’ refusal of rabies and JE vaccination,
including high cost, low perception of benefit, and concern
for an adverse reaction.
17,28–30 Strategic interventions should
be considered to increase the uptake of rabies and JE vaccines
pre-travel in these at-risk populations.
31
During 2010, more GTEN HSWs traveled to Haiti than any
other country. Specifically, more medical workers traveled to
Haiti in the first quarter of 2010, likely responding to the
January of 2010 earthquake. Although most HSWs received
malaria chemoprophylaxis during their pre-travel consulta-
tion, a few did not. Malaria prevention, including providing
proper chemoprophylaxis and mosquito protection education,
is essential for travelers to Haiti and similar destinations. In a
recent report, cases of malaria among aid workers occurred
in persons who had not taken malaria chemoprophylaxis, and
no cases were identified among 52 aid workers who took
346 person-weeks of chloroquine prophylaxis.
32 Another study
found that dengue fever and malaria contributed to over
60% of severe disease requiring hospitalization after return
from Haiti.
8
We found that GTEN HSWs traveled a median of 13 days.
Although longer duration of stay can increase the exposure
risk to a number of infections for travelers, HSWs can also be
at risk during short trips. For example, in a 2008 humanitarian
mission to the Dominican Republic, 14 of 33 missionaries
acquired dengue fever after being in the country for fewer
than 10 days.
7 In another study, 7 of 28 travelers acquired an
acute dengue infection in Haiti after being in the country for
approximately 1 week.
10
Our analysis has several limitations. First, GTEN may not
be representative of the healthcare provided to individuals
traveling internationally from the United States. GTEN prac-
tices are designated YF vaccination centers and therefore,
have some specialized experience in travel medicine. As such,
the proportion of travelers vaccinated or given medications at
GTEN clinics may be different than the proportion in clinics
with no specialization in travel medicine. Second, this analysis
does not include international travelers who do not seek
healthcare before going abroad.
12 Third, we relied on self-
reported data from travelers, and consistent with general clin-
ical practice, serologic confirmation of immunization history
was infrequent. Fourth, although the GTEN reporting tool is
standardized, there may have been variability in clinician
usage and response. Specifically, because the GTEN report-
ing tool is standardized, we were unable to evaluate each
clinical encounter, and we understand that there may be
nuances in individual cases that determine the suitability of
recommending for or against certain vaccines. Fifth, we do
not know whether HSWs received additional consultation,
vaccinations, or prescriptions outside of the GTEN pre-travel
consultation. For rabies vaccination, clinicians were prompted
to enter reasons for non-vaccination only when the traveler
was leaving for longer than 28 days; therefore, the tool did not
prompt vaccination for shorter-term travelers who could still
have a high risk of exposure based on elements of their itiner-
ary other than duration of stay. Sixth, because subnational
data were not available, we could only assess the suitability
of malaria chemoprophylaxis recommendations in those
HSWs traveling to countries holoendemic for malaria. Lastly,
those HSWs who indicated that they were providing medical
service may not be representative of all healthcare workers.
HSWs and the agencies that support their missions should
consider pre-travel healthcare as an integral part of their
travel preparation. To limit the risk of illness and injury,
HSWs must coordinate with the agencies that support their
missions, primary care providers, and travel medicine special-
ists. HSWs need to take an active role in preparing for healthy
travel by gathering information about their travel destinations
and possible activities, especially when traveling to emer-
gency relief areas and engaging with local populations, no
matter the duration of travel. Agencies supporting the mis-
sions of HSWs must understand the value of the pre-travel
health consultation and encourage their HSWs to seek pre-
travel care. In addition, primary care providers need to take
an active role in understanding travel medicine, because an
increasing number of international travelers seek pre-travel
advice from primary care providers compared with other
health information sources.
33,34 Clinicians can use the itiner-
ary details outlined by HSWs and their agencies to tailor
specific recommendations, immunizations, and medications
that are appropriate for the mission. Clinicians should stay
up to date on current travel medicine recommendations and
work to reduce gaps in vaccination among travelers, espe-
cially those who may have future travel to areas at risk. As
such, clinicians can use the pre-travel health consultation as
an opportunity to administer routine vaccines, such as hepati-
tis B, to travelers who may not have received the vaccine
in the past. Taking these steps may reduce the risk of illness
in HSW travelers.
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